



Published in final edited form as:

*J Viral Hepat.* 2018 December ; 25(12): 1582–1587. doi:10.1111/jvh.12974.

## Prevalence and vaccination coverage of Hepatitis B among healthcare workers in Cameroon: A national seroprevalence survey

Chaneline Bilounga Ndongo<sup>\*1</sup>, Lucrèce Eteki<sup>\*2</sup>, Mark Siedner<sup>3,4,5,6</sup>, Rose Mbaye<sup>2</sup>, Jennifer Chen<sup>3,7</sup>, Rodrigue Ntone<sup>2</sup>, Olivier Donfack<sup>2</sup>, Brian Bongwong<sup>8</sup>, Rachel Essaka Evoué<sup>9</sup>, Florence Zeh<sup>1</sup>, Richard Njouom<sup>10</sup>, Georges Nguefack-Tsague<sup>11</sup>, Georges Alain Etoundi Mballa<sup>1</sup>, Magloire Biwole Sida<sup>11</sup>, Yap Boum<sup>2,6</sup>

<sup>1</sup>Department for the control of Disease, Epidemics and Pandemics, Ministry of Public Health, Yaoundé, Cameroon <sup>2</sup>Epicentre, Yaoundé, Cameroon <sup>3</sup>Harvard Medical School, Boston, USA <sup>4</sup>Center for Global Health, Massachusetts General Hospital, Boston, Massachusetts. <sup>5</sup>Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. <sup>6</sup>Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda <sup>7</sup>Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts <sup>8</sup>Department of Public Health, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon <sup>9</sup>Laboratoire du Lac, Yaoundé, Cameroon <sup>10</sup>Centre Pasteur, Yaoundé, Cameroon <sup>11</sup>Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon

### Abstract

**Introduction:** Hepatitis B virus (HBV) infection is hyperendemic in Cameroon, and health care workers (HCWs) are at high-risk of infection. We aimed to assess prevalence, risk factors and vaccine coverage of HBV infection among HCWs in Cameroon.

**Methods:** We conducted a cross-sectional study in 16 hospitals across all regions of Cameroon. HCWs were tested for HBV using rapid diagnostic tests (RDT). We collected data on socio-demographics and HBV vaccination status. We estimated prevalence of HBV and used Poisson regression models with robust standard errors to model the prevalence ratios of HBV positivity between covariates.

**Results:** We enrolled 1,824 of 1,836 eligible HCWs (97.5%). The mean age was 34 (SD: 10) years, 65.3% (n=1787) were women, and 11.4% (n=1747) had three or more doses of the HBV vaccine. Overall, we found a HBV prevalence of 8.7% (95% CI: 5.2 – 14.3%). Patient transporters had the highest crude prevalence (14.3%; 95% CI: 5.4–32.9%), whereas medical doctors had the lowest (3.2%; 95% CI: 0.8%–12.1%). The Far North Region had the highest prevalence of HBV (24.0%; 95% CI: 18.3%–30.8%). HBV prevalence decreased with increasing doses of the HBV vaccine (10.3% for no doses vs 3.5% for three or more doses; P<0.001).

\*CBN and LE contributed equally to this research

**Conflicts of Interest declaration for all authors:** The authors declare no conflict of interest.

**Conclusion:** Approximately 1 in 12 HCWs in Cameroon have evidence of HBV infection, yet fewer than 1 in 6 have been fully vaccinated. Our results illustrate the urgent need to scale up systematic HBV screening and targeted vaccination of HCWs in the region.

### Keywords

Hepatitis B; prevalence; health care workers; vaccine efficacy; Cameroon

More than 2 billion people have been infected with Hepatitis B virus (HBV) globally, and 240 million are chronic carriers of the disease.<sup>1,2</sup> Africa is considered to be endemic for HBV; and the disease is hyperendemic in Cameroon where prevalence has been estimated at 11.9%.<sup>3,4</sup> Health care workers (HCWs) are one of the most vulnerable groups to HBV infection from occupational exposures, with up to four times greater risk of contracting the infection than the general population.<sup>5</sup> Although Cameroon introduced the anti-HBV vaccine in their expanded program of immunization in 2005, this program does not cover most HCWs as they were largely born before 2005.<sup>6</sup> Moreover, there is a lack of awareness of HBV knowledge and practices among HCWs in sub-Saharan Africa, which further contributes to their risk, and that of their patients.<sup>2</sup> Indeed, despite the established elevated risks of HBV infection in hospital settings, documented vaccination rates in small regional studies among HCWs in Cameroon remain low.<sup>6</sup>

However, to our knowledge, no study has rigorously estimated the prevalence of HBV infection among HCWs across all regions of Cameroon.<sup>7</sup> Therefore, we conducted a Hepatitis B surface antigen (HBsAg) seroprevalence survey in a large sample of HCWs across all ten regions of Cameroon. We also assessed the vaccination status and correlates of HBV infection among this highly vulnerable group to identify areas for prevention, intervention, and populations to target with them.

## METHODS:

### Study design and setting

This was a hospital based, cross-sectional study, conducted between July and August 2016. Sixteen national and regional hospitals across the 10 regions of Cameroon were selected.

### Sampling procedures, data and sample collection

All HCWs in selected hospitals were informed and invited for HBsAg testing. Testing stations were set up in each hospital ward. All active healthcare personnel, older than 18 years, working as HCWs were eligible for inclusion in this study. We aimed to recruit a total of 2,000 HCWs based on the number of tests available for this study. We obtained national proportions of HCWs per region from a registry published in 2015.<sup>8</sup> We then applied these national proportions to our sample size to obtain the self-weighted target number of HCWs per region (Table 1). Consenting participants completed a structured questionnaire to collect data on sociodemographic characteristics, HBV exposure risks, HBV vaccination, and prevention methods. Whole blood was collected from each participant by venipuncture into ethylenediaminetriacetic acid and serum separator tubes. HBsAg was tested using the

SelexOn lateral flow assays (SelexOn, Infopia, Seoul, Korea) on 100 $\mu$ L of whole blood according to manufacturer instructions.

### Statistical analysis

Data were entered into Microsoft Excel (Microsoft, Redmond, Washington). Statistical analyses were performed using Stata version 13 (StataCorp, College Station, TX). Data was described using count (percent) and chi-squared testing was used to test associations between categorical variables. We used Poisson regression with robust standard errors to assess the independent associations between HBV prevalence and covariates, including region, vaccination status, sex, age, and profession. Vaccine efficacy was calculated as 1 - [prevalence among participants with 3 doses of HBV vaccine (i.e. fully vaccinated)/prevalence among participants with 0 doses of vaccine] to estimate the efficacy of HBV vaccination.

### Ethics Statement

This study was approved by the National Ethics Committee of Cameroon. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. All participants signed informed consent.

## RESULTS

A total of 1,824 participants were enrolled in this study. The mean age was 34 (SD:10) years. Women represented 65.3% (1167/1787) of this population. We tested 1,790 for HBsAg. Nurses were the most represented profession (35.2%; 626/1779), whereas medical doctors made up the smallest proportion of the sample (3.5%; 62/1779). Nearly two thirds of the participants had less than five years of experience. We found that 23% (403/1754) of the participants had received at least one dose of the vaccine, while only 11.4% (200/1747) completed the recommended three shots vaccination series ( $P<0.001$ ).

The overall prevalence of HBV was 8.7% (156/1790 95%CI: 5.2 – 14.3%). Table 2 summarizes HBV prevalence by key demographic characteristics. The prevalence was higher in men than in women [13.0% (81/620; 95% CI: 10.6 – 16.0%) vs 6.3% (74/1167; 95% CI: 5.1 – 7.9%),  $P<0.001$ ]. HBV prevalence varied significantly ( $P<0.001$ ) across regions ranging from 5.1% (9/175; 95%CI: 2.7 – 9.6%) in the Southwest region to 24.0% (43/179; 95%CI: 18.3 – 30.8%) in the Far North Region.

HCWs who were vaccinated had a significantly lower prevalence of HBV than those who were not vaccinated [3.5% (14/403; 95%CI: 2.0 – 5.8%) vs 10.3% (140/1351; 95%CI: 8.8 – 12.1%);  $P<0.001$ ]. We also found that the prevalence decreased with increasing number of vaccine doses (figure 1). Overall vaccine efficacy against HBV infection was 85% (95%CI: 55–95%). Furthermore, we observed that HCWs that were professionally trained (medical doctors, nurses, laboratory technicians) had a higher vaccination coverage than ancillary staff (patient transporters, sanitation staff, others) (26.2% (350/1337; 95%CI: 23.9 – 28.6%) vs 14.4% (64/445; 95%CI: 11.4 – 17.9%);  $P<0.001$ , Table 3). Although the difference in prevalence by profession was not significant ( $P=0.19$ ), we observed that medical doctors and

laboratory technicians had the lowest crude prevalence of HBV 3.2% (2/62; 95%CI: 0.8–12.1%) and 3.6% (4/110; 95%CI: 1.4–9.3%) respectively.

### Adjusted risk factors for HBV infection

Using a Poisson regression model with robust standard errors (Table 4) we found that participants in the Far North region had nearly three times the prevalence (APR 2.8; 95%CI 2.0–4.0%;  $P<0.001$ ) of participants from other regions of Cameroon. We also found that non-vaccinated HCWs had 2.7 times the prevalence of vaccinated participants (95%CI: 1.6–4.6%,  $P<0.001$ ). Women had 40% lower prevalence of HBV compared to men (APR=0.6; 95% CI 0.4–0.9%;  $P<0.001$ ).

## DISCUSSION

In this national seroprevalence study in Cameroon, we found an alarmingly high HBsAg prevalence of 8.7% among HCWs. HBV infection was particularly common in men, in non-vaccinated staff, and in the Far North region of Cameroon. These data corroborate others from tertiary hospitals in Tanzania and Uganda, which also found remarkably high prevalence of HBsAg positivity in HCWs, at 7.0% and 8.1% respectively.<sup>25</sup> Our findings are also comparable to estimates in other high-risk groups in Cameroon. Frambo *et al* reported a prevalence of 9.7% among pregnant women, and Noubiap *et al* reported a prevalence of 10.1% in blood donors.<sup>9,10</sup> Despite the importance of the problem, most studies on HCWs are done on small samples sizes. A recent systematic review of the seroprevalence of HBV infection in Cameroon found only four relevant studies on HCWs, and none of them covered all regions of the country.<sup>7</sup> Our study is the first to our knowledge conducted across all the regions of Cameroon, and illustrates an important and readily addressable public health problem in the region.

Our results also reinforce both the value and unmet need of vaccination for HCWs in Cameroon. Less than one in four HCWs in our sample had received any immunizations against HBV, of whom only approximately 1 in 10 had received the three recommended doses. Importantly, only 12.1% of the HbsAg negative participants were fully vaccinated – indicating a significant opportunity for disease prevention. Although professionally trained personnel tended to be more likely to be vaccinated than ancillary staff (26.2% vs 14.4%), all groups remained well below target, indicating the necessity to establish vaccination programs in this high risk population. Not surprisingly, we found that HBV prevalence significantly decreased with increasing number of HBV vaccine doses, and estimated a vaccine efficacy of 85%. This result is similar to CDC estimates which indicate that the vaccine is 80% to 100% effective in preventing infection or clinical hepatitis in those who receive the complete vaccine series.<sup>11</sup> Our findings reinforce the effectiveness of the complete vaccination schedule and the value of completing in high risk populations.

Several studies have demonstrated high rates of naturally acquired immunity ranging from 60–90% among adults in endemic countries, particularly in sub-Saharan Africa where infections occur perinatally or during childhood.<sup>12</sup> Ideally, targeted vaccination programs that identify individuals who are HBsAg positive and those who are HBcAb negative would be more efficient. As in many resources limited countries, the cost of determining anti-HBs

titers is higher than the cost of the HBV vaccination series. Specifically in Cameroon, the cost of vaccination can be as low as 3.50 USD while determining anti-HBc titers can cost up to 17 USD<sup>13,14</sup>. Because vaccination remains the primary means of prevention against HBV infection, and because it has clear secondary public health benefits in HCWs, vaccination of this population should be prioritized. WHO has specified that HCWs require additional attention for HBV screening and vaccination.<sup>15</sup> However, our results highlight that these recommendations are not yet well implemented in low and middle income countries such as Cameroon.

Our results also demonstrated that HCWs from the Far North have the greatest burden of HBV. We hypothesize that this is explained by the fact that the Far North is located in a zone of political instability and conflict, and is likely to be contributing to both decreased rates of HBV screening and vaccination.<sup>16</sup> The risk of contracting HBV in resource-limited settings and areas of conflict has been demonstrated to be significantly higher due to a combination of factors including: poor vaccine coverage, poor educational attainment, inadequate prevention and screening strategies, frequent iatrogenic transmission, and limited access to treatment.<sup>17</sup> Consequently, additional resources and attention is likely to be needed in the Far North region in Cameroon and similarly conflict-affected regions.

Finally, our results should prompt more formal consideration of access to HBV treatment programs in the region. Although additional testing is needed to risk stratify those with a positive HBsAg test, our study highlights an important need to decentralize HBV treatment in Cameroon to minimize the substantial long term morbidity associated with untreated HBV infection.

#### **Limitations:**

Although this study was conducted across all regions of Cameroon, our sample might not be representative of the national HCWs distribution because we used convenience sampling. As recommended by the WHO, we used a RDT to test for HBsAg. However, the use of a RDT might underestimate the prevalence of HBV as compared to a reference testing method such as enzyme linked immunosorbent assays.<sup>18</sup> Information about vaccination status and doses were self-reported and might be subject to recall bias, which can affect estimation of vaccine efficacy. Furthermore, our estimate of vaccine efficacy does not take into consideration the timing of vaccination in relation to the timing of infection as the data was collected retrospectively.

In conclusion, we found a considerable burden of HBV infection among HCWs in Cameroon, particularly among men, ancillary staff and residents of the unstable Far North region. Moreover, the vaccination coverage was alarmingly low among this high-risk population, highlighting the need and opportunity for testing and vaccination strategies specifically designed for HCWs in the region. Such programs could have far reaching public health benefits both for our HCWs and the patients they serve.

#### **ACKNOWLEDGEMENTS:**

We thank S. Ewale Bah for his contribution in planning the implementation of this study. We are grateful to J. Mendouga, S. Njimo, P. Ndoh, D. Mougoue, W. Tenlep, M. Soua, A. Osteng, H. Nanda, B. Djonga, R. Sandjong

who collected samples in hospitals across the country, and to the Regional Hospitals management for facilitating the study. We are indebted to the HCWs who participated in the study. We thank Infopia, Korea who donated the Selexon RDT and cartridges that were used to test for HBV. We thank Médecins Sans Frontières and Laboratoire du Lac for the logistic support they provided. This study was funded by the Ministry of Public Health of Cameroon. The sponsor had no role in the design, data collection, analysis, interpretation, or writing of this paper, nor in the decision to submit for publication.

**Statement of financial support:** The study was sponsored and coordinated by the Ministry of Public Health of Cameroon.

### List of abbreviations in the order of appearance:


<b>HBV</b>	Hepatitis B Virus
<b>HCWs</b>	Health Care Workers
<b>RDT</b>	Rapid Diagnostic Tests
<b>HBsAg</b>	Hepatitis B Surface Antigen
<b>HBcAb</b>	Hepatitis B Core Antibody

### REFERENCES:

1. WHO. WHO | Hepatitis B WHO <http://www.who.int/mediacentre/factsheets/fs204/en/>. Published 2017 Accessed October 16, 2017.
2. Mueller A, Stoetter L, Kalluvya S, et al. Prevalence of hepatitis B virus infection among health care workers in a tertiary hospital in Tanzania. *BMC Infect Dis* 2015;15:386. doi:10.1186/s12879-015-1129-z. [PubMed: 26399765]
3. Zampino R, Boemio A, Sagnelli C, et al. hepatitis B virus burden in developing countries 2015 *Advances in Hepatitis B virus. World J Gastroenterol* 2015;21(42):11941–11953. doi:10.3748/wjg.v21.i42.11941. [PubMed: 26576083]
4. NJOUOM R, FONTANET A. Épidémiologie Des Hépatites Virales B, C, et Delta Au Cameroun: Analyse Des Échantillons de L'enquête Démographique de Santé 2011; 2011 <http://anrs-cameroun.org/anrs-12289>. Accessed October 16, 2017.
5. Ziraba AK, Bwogi J, Namale A, Wainaina CW, Mayanja-Kizza H. Sero-prevalence and risk factors for hepatitis B virus infection among health care workers in a tertiary hospital in Uganda. *BMC Infect Dis* 2010;10. doi:10.1186/1471-2334-10-191. [PubMed: 20082697]
6. Fritzsche C, Becker F, Hemmer CJ, et al. Hepatitis B and C: neglected diseases among health care workers in Cameroon. *Trans R Soc Trop Med Hyg* 2013;107:158–164. doi:10.1093/trstmh/trs087. [PubMed: 23303802]
7. Bigna JJ, Amougou MA, Asangbeh SL, et al. Seroprevalence of hepatitis B virus infection in Cameroon: a systematic review and meta-analysis. *BMJ Open* 2017;7(6):e015298. doi:10.1136/bmjopen-2016-015298.
8. Tandji TE, Cho Y, Akam AJ-C, et al. Cameroon public health sector: shortage and inequalities in geographic distribution of health personnel. *Int J Equity Health* 2015;14(1):43. doi:10.1186/s12939-015-0172-0. [PubMed: 25962781]
9. Frambo AA, Atashili J, Fon P, Ndumbe P. Prevalence of HBsAg and knowledge about hepatitis B in pregnancy in the Buea Health District, Cameroon: a cross-sectional study. *BMC Res Notes* 2014;7(1):394. doi:10.1186/1756-0500-7-394. [PubMed: 24965844]
10. Noubiap JJN, Joko WYA, Nansseu JRN, Tene UG, Siaka C. Sero-epidemiology of human immunodeficiency virus, hepatitis B and C viruses, and syphilis infections among first-time blood donors in Edéa, Cameroon. *Int J Infect Dis* 2013;17(10):e832–e837. doi:10.1016/j.ijid.2012.12.007. [PubMed: 23317526]
11. CDC. Pinkbook | Hepatitis B | Epidemiology of Vaccine Preventable Diseases | CDC. <https://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html>. Accessed March 1, 2018.

12. Pellissier G, Yazdanpanah Y, Adehossi E, et al. Is Universal HBV Vaccination of Healthcare Workers a Relevant Strategy in Developing Endemic Countries? The Case of a University Hospital in Niger. Bisser S, ed. PLoS One 2012;7(9):e44442. doi:10.1371/journal.pone.0044442. [PubMed: 22970218]
13. Centre Pasteur du Cameroun. <http://www.pasteur-yaounde.org/files/catalogue2016.pdf>. Accessed June 21, 2018.
14. Cameroun : Seulement 2000 Fcfa pour se vacciner contre l'hépatite B - Actu Cameroun <https://actucameroun.com/2017/08/15/cameroun-seulement-2000-fcfa-pour-se-vacciner-contre-lhepatite-b/>. Accessed June 21, 2018.
15. World Health Organization. Global Hepatitis Programme. Guidelines for the prevention, care, and treatment of persons with chronic hepatitis B infection 2015;(3):134 [http://www.worldcat.org/title/guidelines-for-the-prevention-care-and-treatment-of-persons-with-chronic-hepatitis-b-infection/oclc/907556882&referer=brief\\_results](http://www.worldcat.org/title/guidelines-for-the-prevention-care-and-treatment-of-persons-with-chronic-hepatitis-b-infection/oclc/907556882&referer=brief_results).
16. Noubiap JJN, Nansseu JRN, Ndoula ST, Bigna JJR, Jingi AM, Fokom-Domgue J. Prevalence, infectivity and correlates of hepatitis B virus infection among pregnant women in a rural district of the Far North Region of Cameroon. BMC Public Health 2015;15:454. doi:10.1186/s12889-015-1806-2. [PubMed: 25933803]
17. Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol 2013;8(4):371–380. doi:10.2217/fvl.13.11. [PubMed: 23662157]
18. Kukar Neetu; Garg Ravinder; Maharishi R; Syal Neha; Arora Harkiran; Handa A. ELISA versus Rapid test kits for screening of HIV and Hepatitis B and Hepatitis C among Blood donors in a tertiary care hospital. Sch J Appl Med Sci 2017;(5 (3A)):727–729. doi:10.21276/sjams.2017.5.3.9.





**Figure 1:**  
HBV vaccination doses vs HBV prevalence



**Table 1:**

## Sample distribution

<b>Region</b>	<b>Targeted number of participants</b>
Centre	555
Littoral	296
Far North	218
West	246
North West	151
South West	188
South	75
East	87
Adamawa	69
North	115
<b>Total</b>	<b>2000</b>

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 2:**

HBV prevalence rate by category

Variable	n	HBsAg+	Prevalence, in % (95% CI)	P-value
Sex				
Male	620	81	13.0 (10.6 – 16.0)	<0.0001
Female	1167	74	6.3 (5.1 – 7.9)	
Age				
<=25	451	44	9.7 (7.3– 12.9)	0.28
26–39	818	75	9.2 (7.4 – 11.4)	
>=40	521	37	7.1 (5.2 – 9.7)	
Region				
Adamaoua	69	7	10.1 (4.9 – 19.9)	<0.0001
Centre	425	23	5.4 (3.6 – 8.0)	
Est	85	4	4.7 (1.7 – 11.9)	
Far North	179	43	24.0 (18.3 – 30.8)	
Littoral	273	17	6.2 (3.9 – 9.8)	
Nord	194	23	11.8 (8 – 17.2)	
North West	139	11	8.0 (4.4 – 13.7)	
West	176	10	5.7 (3 – 10.2)	
South	75	9	12.0 (6.3 – 21.6)	
South West	175	9	5.1 (2.7 – 9.6)	
Prior Vaccination				
No	1351	140	10.3 (8.8 – 12.1)	<0.0001
Yes	403	14	3.5 (2.0 – 5.8)	
Vaccination doses				
0	1351	140	10.3 (8.8– 12.0)	<0.0001
1	101	6	6.0 (2.7–12.7)	
2	95	4	4.2 (1.6–10.8)	
3	185	3	1.5 (0.5–4.8)	
>3	15	0	0.0	
Profession				
Medical Doctor	62	2	3.2 (0.8–12.1)	0.19
Nurse	626	50	8.0 (6.1–10.4)	
Intern	535	52	9.7 (7.5–12.5)	
Laboratory Technician	110	4	3.6 (1.4–9.3)	
Patient-transporter	28	4	14.3 (5.4–32.9)	
Cleaning Agent	132	13	9.8 (5.8–16.3)	
Others	286	27	9.4 (6.5–13.4)	
Working Experience, in years				

Variable	n	HBsAg+	Prevalence, in % (95% CI)	P-value
<=1	582	55	9.4 (7.3 – 12.1)	0.34
2-5	469	45	9.6 (7.2 – 12.6)	
6-10	333	29	8.7 (6.1 – 12.3)	
>10	387	25	6.4 (4.4 – 9.4)	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 3:**

Vaccination coverage for professional vs ancillary HCWs

HCWs Categories	n	Number of vaccinated HCWs	Percentage of vaccinated HCWs(95%CI)	P-value
Professional staff (Medical Doctors, Nurses, Laboratory Technicians)	1337	350	26.2 (23.9 – 28.6)	<0.0001
Ancillary staff (Patient transporters, Cleaning Agents, Others)	445	64	14.4 (11.4 – 17.9)	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 4:**

Risk factors for contracting HBV

Variables	Adjusted prevalence ratio	P-value	95% CI
Region (ref=all other regions)			
Extreme North	2.8	<0.001	2.0 – 4.0
Vaccination status (ref=vaccinated)			
Non-vaccinated	2.7	<0.001	1.6 – 4.6
Sexe (ref=male)			
Female	0.6	0.004	0.4 – 0.9
Age (ref<=25)			
26–39	1.2	0.41	0.8 – 1.7
>=40	0.9	0.56	0.5 – 1.4
Profession (ref=professionals)			
Ancillary	1.2	0.37	0.8 – 1.7

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript